The PennZone

  • Home
  • Non-profit
  • Music
  • Books
  • Entertainment
  • Marketing
  • Legal
  • Health
  • Automotive

ExpressCells to Present in BIO Start-Up Stadium Next Week
The PennZone/10070540

Trending...
  • Harvard Educated Board Certified Endodontist Joins Pearlfection Dentistry
  • Wilson Venture Capital to Launch News Organization; Will Name Trevor Wilson CEO
  • Turnstone Creative Welcomes Giovanni Amodei as Manager of Strategic Growth
Company is one of 30 selected for prestigious competition. During BIO Digital Week, attendees can watch timely, on-demand pitches and meet with ExpressCells via BIO's One-on-One Partnering.

PHILADELPHIA - PennZone -- ExpressCells, Inc. (ExpressCells), a privately-owned genetic engineering company that creates knock-in cell lines for drug discovery, will be one of the finalists presenting in the Start-Up Stadium during BIO Digital Week.

"We are honored to be selected by the judges as one of the finalists for Start-Up Stadium. We hope that all BIO Digital Week attendees view our presentation, which will be available on demand via the meeting platform."

Start-Up Stadium provides an exciting and interactive experience where key stakeholders of the early-stage life science community, investors, and strategic partners provide feedback and judge 6 minute pitches presented by start-up biotech companies. During BIO Digital Week, attendees can watch ExpressCells' pitch on-demand and meet with the company via BIO's One-on-One Partnering.

More on The PennZone
  • netElastic Announces vBNG And CGNAT 2.0 General Availability
  • Postmortem Pathology Highlights Private Autopsy Options for Las Vegas Families During Summer Months
  • Postmortem Pathology Offers Sacramento Families Independent Answers on a Short Timeline
  • Philly ECM Programming Announces Mobile Module Programming for Philadelphia Repair Shops
  • NEW Three Fully Furnished Single-Family Model Homes at Heritage at South Brunswick

"ExpressCells is excited to be part of BIO Digital Week," Mr. Handel continued. "We hope to gain valuable feedback and to meet with both potential customers and potential investors.

About ExpressCells

ExpressCells is a private biotechnology company based in Philadelphia, PA. Its propriety genome editing technology, in combination with CRISPR/Cas9, creates advanced, knock-in cell line up to 75% faster than older processes. This technology allows ExpressCells to insert up to three genes into the same cell line.

ExpressCells' first knock-in cell lines code for bioluminescent and fluorescent proteins. These allow scientists to more see the results of their experiments in real time. ExpressCells sells both custom cell lines—each designed to meet the specific requirements of an individual scientist—and catalog cell lines. For more information, visit www.xpresscells.com.

Contact
Matthew Handel
***@xpresscells.com
+1 (484) 483-6759


Source: ExpressCells, Inc.

Show All News | Disclaimer | Report Violation

0 Comments
1000 characters max.

Latest on The PennZone
  • Scoop Social Co. Brings Its Signature Mobile Dessert Experience to Phoenix
  • SMACK Fighting Championships Announces Influencer Fight Night at Harrah's Philadelphia
  • BetQL Brings Data Driven 5 Star Betting Insights to the Everyday Sports Bettor
  • Sky Quarry's Big Turning Point: CEO Marcus Laun Outlines the Next Phase for N A S D A Q: SKYQ
  • Hunter Is Releasing New Music For The Holidays!
  • Tixpool.com - Naija Premier Event Reseller
  • Work 365 Expands Distributor Integrations with Companial for Microsoft Partners
  • ClassicCarJobs.us Launches Automotive Career Marketplace for Specialty Shops
  • Guardian Data Opens 42,000-Square-Foot Moonachie Facility, Doubling New Jersey Capacity
  • Dutch Mill Bulbs Launches Pink Ribbon Tulip Fundraise ~ National Breast Cancer Foundation, Inc.®
  • SecureMaine 2026 is Here -- Thursday October 8th!
  • Bluestone Laundromat Makes a Difference in the Archbald Community
  • HW Foundation Opens Nominations for Inaugural 50 Under 50 in AI; Deadline Oct. 16
  • Pavillon 30 Years of Addiction Recovery in Western North Carolina, Earns National Accreditation
  • ResC4EU Final Event at KOMPOZYT-EXPO 2026 – Building Resilient European Supply Chains
  • BJJ App mmaGPT Expands Academy Program to Support Jiu-Jitsu Instructors with AI Technique Coaching
  • Ten Ten Ten Announces Maximizing Clinical Operations
  • Turnstone Creative Welcomes Giovanni Amodei as Manager of Strategic Growth
  • CardsNearby Launches Free Nationwide Directory of Card Shows and Local Card Shops for Collectors
  • American Garden Rose Selections™ Announces 2027 Winners

Popular on PennZone

  • FDA-Cleared Zeta TMS Robotic System Moves Toward Deployment as FDA, DARPA and Commercial Catalysts Converge: NRx Pharmaceuticals (N A S D A Q: NRXP)
  • Mandeville Pests May Pose Serious Health Risks for Your Family
  • Garage door installation or repair in Minnesota? Which makes more sense for your family?
  • The Culture and Travel Report Enters a New Chapter as Travel and Hospitality Brands Take Notice
  • STS Capital Partners is pleased to announce the appointment of Barry Brown as Vice President, Business Development
  • New Bethany's 35th Annual Souper Day to Spotlight Connection Between Health, Hunger and Housing
  • Regcrest LLC Publishes Free 50-State Tax Account Closure Checklist Tool
  • A New Tale Band Makes 9/11 Tribute Song "The Twins" Free for Ceremonies and School Programs
  • Allstream Energy Partners Nominated in Multiple Categories for Fast Company's Best Workplaces for Innovators
  • Congressman Chuck Edwards (NC-11) Presents ReadyCommunities Partnership 2026 National Service Award to Local Businessman / US Air Force Veteran

Similar on PennZone

  • $11.18 Million DARPA Award Ignites a Major New Catalyst as FDA, Robotic TMS and Commercialization Milestones Converge for NRx Pharmaceuticals, Inc
  • Nutriband (N A S D A Q: NTRB): Fighting Back Against the Fentanyl Crisis With a New Approach to Safer Transdermal Medicines
  • Most Utah Deaths Never Reach the Medical Examiner. Postmortem Pathology Offers Salt Lake City a Private Autopsy Option
  • Nutriband Inc. (N A S D A Q: NTRB) Breaks Into Uncharted Territory: 52-Week High Eclipsed as Shares Surge 22% —AVERSA™ Puts Investors on High Alert
  • Thar Process Partners with French Leader ExtrateX to Bring Prep to Process-Scale SFC to Europe
  • Biophysical Therapeutics brings longevity science to skincare with its new IF1 brand
  • ClearSight Therapeutics Receives NIH SBIR Phase I Award for Conjunctivitis and EKC Research
  • Lunai Bioworks (N A S D A Q: LNAI) Takes Parkinson's Discovery to the Next Level With Exclusive Tanaist Agreement
  • Independent Autopsies Are Changing Civil Cases: Kansas City Forensic Explains Why Families Are Seeking Second Opinions
  • Warrant Activity, AVERSA™ Progress and a Potentially Transformative Fall Take Center Stage: Nutriband Inc. (N A S D A Q: NTRB)
Copyright © The PennZone | Theme: OMag by LilyTurf Themes
  • Contribute
  • Privacy Policy
  • Terms of Service
  • Contact Us